Pf Prism Cv Drug Patent Portfolio

Pf Prism Cv owns 11 orange book drugs protected by 75 US patents with Vfend having the least patent protection, holding only 2 patents. And Torisel with maximum patent protection, holding 14 patents. Given below is the list of Pf Prism Cv's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10869924 PD-L1 antagonist combination treatments 12 Jul, 2037
Active
US10869924 PD-L1 antagonist combination treatments 12 Jan, 2037
Active
US10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer 03 Aug, 2035
Active
US10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer 03 Feb, 2035
Active
US11103497 Treatment of imatinib resistant leukemia 28 Aug, 2034
Active
US11103497 Treatment of imatinib resistant leukemia 28 Feb, 2034
Active
US8791097 Anti-tumor activity of CCI-779 in papillary renal cell cancer 10 Nov, 2032
Active
US8791097 Anti-tumor activity of CCI-779 in papillary renal cell cancer 10 May, 2032
Active
US8791140 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals 14 Jun, 2031
Active
US8791140 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals 14 Dec, 2030
Active
US8372995 Crystalline solid forms of tigecycline and methods of preparing same 08 Oct, 2030
Active
US8217057 Polymorphs of a c-MET/HGFR inhibitor 06 Nov, 2029
Active
US7858643 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors 08 Oct, 2029
Active
US7879828 Tigecycline compositions and methods of preparation 05 Feb, 2029
Active
US8975242 Tigecycline compositions and methods of preparation 24 Oct, 2028
Active
US8269040 Derivatives of venlafaxine and methods of preparing and using the same 05 Jul, 2027
Active
US7767678 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same 23 May, 2027
Active
US7825137 Method of treating abnormal cell growth 12 May, 2027
Active
US7767678 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same 23 Nov, 2026
Active
US8026276 Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant 20 Jul, 2026
Active
US7417148 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Jun, 2026
Active
US7919625 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Jun, 2026
Active
US10588975 Tigecycline compositions and methods of preparation 13 Mar, 2026
Active
US9254328 Tigecycline compositions and methods of preparation 13 Mar, 2026
Active
US9694078 Tigecycline compositions and methods of preparation 13 Mar, 2026
Active
US8026276 Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant 20 Jan, 2026
Active
US7417148 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Dec, 2025
Active
US7919625 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Dec, 2025
Active
USRE41783 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2025
Active
US6534524 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 29 Oct, 2025
Active
US7230098 Aminoheteroaryl compounds as protein kinase inhibitors 26 Aug, 2025
Active
US6534524 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 29 Apr, 2025
Active
US8785632 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors 01 Mar, 2025
Active
USRE42376 Substituted 3-cyanoquinolines 13 Oct, 2024 Expired
USRE42376 Substituted 3-cyanoquinolines 13 Apr, 2024 Expired
US6984403 Azithromycin dosage forms with reduced side effects 14 Feb, 2024 Expired
US7887844 Multiparticulate crystalline drug compositions having controlled release profiles 14 Feb, 2024 Expired
US8299116 CCI-779 concentrate formulations 25 Jan, 2024 Expired
US8455539 CCI-779 concentrate formulations 25 Jan, 2024 Expired
US8722700 CCI-779 formulations for parenteral administration 25 Jan, 2024 Expired
US8299116 CCI-779 concentrate formulations 25 Jul, 2023 Expired
US8455539 CCI-779 concentrate formulations 25 Jul, 2023 Expired
US8722700 CCI-779 formulations for parenteral administration 25 Jul, 2023 Expired
US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate 25 Mar, 2023 Expired
US7265119 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 03 Feb, 2023 Expired
US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 06 Nov, 2022 Expired
US7265119 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 03 Aug, 2022 Expired
US7301023 Chiral salt resolution 23 May, 2022 Expired
US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 06 May, 2022 Expired
US6673838 Succinate salt of O-desmethyl-venlafaxine 01 Mar, 2022 Expired
US6956041 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020 Expired
US7091208 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020 Expired
US7265221 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020 Expired
US7842699 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020 Expired
US6410550 Aryl fused azapolycyclic compounds 10 Nov, 2020 Expired
US7141581 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 30 Jun, 2020 Expired
US6410550 Aryl fused azapolycyclic compounds 10 May, 2020 Expired
USRE44768 Rapamycin hydroxyesters 15 Aug, 2019 Expired
USRE44768 Rapamycin hydroxyesters 15 Feb, 2019 Expired
US5989591 Rapamycin formulations for oral administration 11 Sep, 2018 Expired
US6268489 Azithromycin dihydrate 31 Jul, 2018 Expired
US6632803 Pharmaceutical formulations containing voriconazole 02 Jun, 2018 Expired
US6002008 Substituted 3-cyano quinolines 27 Mar, 2018 Expired
US5989591 Rapamycin formulations for oral administration 11 Mar, 2018 Expired
US6068859 Controlled-release dosage forms of Azithromycin 30 May, 2017 Expired
US5567817 Triazole antifungal agents 24 May, 2016 Expired
USRE40183 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines 09 Apr, 2016 Expired
US5362718 Rapamycin hydroxyesters 18 Oct, 2014 Expired
US5362718 Rapamycin hydroxyesters 18 Apr, 2014 Expired
US5536729 Rapamycin formulations for oral administration 30 Mar, 2014 Expired
US5100899 Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof 07 Jan, 2014 Expired
US5536729 Rapamycin formulations for oral administration 30 Sep, 2013 Expired
US5100899 Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof 07 Jul, 2013 Expired
USRE40086 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines 25 Jun, 2013 Expired
US5403833 Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof 04 Oct, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Pf Prism Cv.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 11 Jul, 2024 US8372995 (Litigated)
Maintenance Fee Reminder Mailed 17 Jun, 2024 US8299116
Payment of Maintenance Fee, 4th Year, Large Entity 05 Jun, 2024 US10869924
Payment of Maintenance Fee, 12th Year, Large Entity 08 Feb, 2024 US8269040 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 14 Dec, 2023 US8217057
Payment of Maintenance Fee, 4th Year, Large Entity 10 Aug, 2023 US10588975
Payment of Maintenance Fee, 4th Year, Large Entity 09 Aug, 2023 US10570202
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jul, 2023 US9254328
Payment of Maintenance Fee, 12th Year, Large Entity 08 Feb, 2023 US8026276
Expire Patent 02 Jan, 2023 US7842699
Payment of Maintenance Fee, 12th Year, Large Entity 14 Sep, 2022 US7919625 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 10 Aug, 2022 US8975242 (Litigated)
Maintenance Fee Reminder Mailed 18 Jul, 2022 US7842699
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jul, 2022 US7879828 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jul, 2022 US7887844


Pf Prism Cv's Drug Patent Litigations

Pf Prism Cv's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Pf Prism Cv's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6890927 June, 2021 Terminated-Settled
(29 Oct, 2021)
Pfizer Inc. Apotex Inc. et al.
US11103497 August, 2019 Decision
(27 Oct, 2020)
Becker Hewes
US7879828 March, 2015 Terminated-Denied
(16 Sep, 2015)
Wyeth LLC Apotex Inc.
US7879828 November, 2013 FWD Entered
(20 Apr, 2015)
Wyeth LLC Apotex Inc.
US7879828 August, 2014 Terminated-Denied
(13 Feb, 2015)
Wyeth LLC Initiative for Responsibility in Drug Pricing LLC
US6673838 May, 2010 Decision
(28 May, 2010)
Anthony F. Hadfield et al
US6268489 January, 1 Decision
(15 Apr, 1998)
ALLEN et al


Pf Prism Cv Drug Patents' Oppositions Filed in EPO

Pf Prism Cv drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 08, 2008, by Lammert, Roland, Dr.. This opposition was filed on patent number EP02718949A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18205542A Jun, 2022 König Szynka Tilmann von Renesse Granted and Under Opposition
EP18205542A May, 2022 Pajaro Limited Granted and Under Opposition
EP18205542A May, 2022 Pohlman, Sandra M. Granted and Under Opposition
EP18205542A May, 2022 Boult Wade Tennant LLP Granted and Under Opposition
EP18205542A May, 2022 Symbiosis IP Limited Granted and Under Opposition
EP18205542A May, 2022 Hoffmann Eitle Granted and Under Opposition
EP18205542A May, 2022 Wuesthoff & Wuesthoff Patentanwälte PartG mbB Granted and Under Opposition
EP15191756A Apr, 2022 SANDOZ AG Granted and Under Opposition
EP15703439A Aug, 2019 König Szynka Tilmann von Renesse Granted and Under Opposition
EP15703439A Aug, 2019 Withers & Rogers LLP Granted and Under Opposition
EP08719405A Feb, 2018 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP12153823A Mar, 2017 Generics (U.K.) Limited Revoked
EP12153823A Mar, 2017 Accord Healthcare Revoked
EP08742616A Mar, 2016 Generics (UK) Limited Opposition rejected
EP12160638A Feb, 2015 Generics (UK) Ltd (trading as Mylan) Opposition rejected
EP06774184A Oct, 2014 Generics [UK] Ltd (trading as Mylan) Patent maintained as amended
EP06774184A Oct, 2014 Fresenius Kabi Deutschland GmbH Patent maintained as amended
EP06737947A Jun, 2014 PENTAFARMA S.A. Patent maintained as amended
EP06737947A Jun, 2014 Hollatz, Christian Patent maintained as amended
EP06737947A Jun, 2014 Hollatz, Christian Patent maintained as amended
EP06737947A Jun, 2014 df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB Patent maintained as amended
EP06760544A Jan, 2014 Taylor Wessing LLP Revoked
EP06760544A Jan, 2014 Galenicum Health S.L. Revoked
EP02781589A Nov, 2011 Wibbelmann, Jobst Opposition rejected
EP04010248A Mar, 2009 Lammert, Roland, Dr. Revoked
EP04010248A Mar, 2009 Wyeth Revoked
EP04010248A Mar, 2009 RANBAXY PHARMACEUTICALS INC. Revoked
EP03771828A Nov, 2008 Wichmann, Hendrik Revoked
EP03771828A Nov, 2008 Teva Pharmaceutical Industries Ltd. Revoked
EP02718949A May, 2008 SEPRACOR Inc Patent maintained as amended
EP02718949A May, 2008 EGIS Gyógyszergyár Nyrt Patent maintained as amended
EP02718949A May, 2008 Lammert, Roland, Dr. Patent maintained as amended


Pf Prism Cv's Family Patents

Pf Prism Cv drugs have patent protection in a total of 62 countries. It's US patent count contributes only to 14.3% of its total global patent coverage. 16 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Pf Prism Cv Drug List

Given below is the complete list of Pf Prism Cv's drugs and the patents protecting them.


1. Bosulif

Bosulif is protected by 11 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11103497
(Pediatric)
Treatment of imatinib resistant leukemia 28 Aug, 2034
(9 years from now)
Active
US11103497 Treatment of imatinib resistant leukemia 28 Feb, 2034
(9 years from now)
Active
US7767678
(Pediatric)
Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same 23 May, 2027
(2 years from now)
Active
US7767678 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same 23 Nov, 2026
(2 years from now)
Active
US7417148
(Pediatric)
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Jun, 2026
(1 year, 7 months from now)
Active
US7919625
(Pediatric)
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Jun, 2026
(1 year, 7 months from now)
Active
US7417148 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Dec, 2025
(1 year, 1 month from now)
Active
US7919625 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) 11 Dec, 2025
(1 year, 1 month from now)
Active
USRE42376
(Pediatric)
Substituted 3-cyanoquinolines 13 Oct, 2024
(a day ago)
Expired
USRE42376 Substituted 3-cyanoquinolines 13 Apr, 2024
(6 months ago)
Expired
US6002008 Substituted 3-cyano quinolines 27 Mar, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bosulif's drug page


2. Chantix

Chantix is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7265119
(Pediatric)
Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 03 Feb, 2023
(1 year, 8 months ago)
Expired
US6890927
(Pediatric)
Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 06 Nov, 2022
(1 year, 11 months ago)
Expired
US7265119 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 03 Aug, 2022
(2 years ago)
Expired
US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof 06 May, 2022
(2 years ago)
Expired
US6410550
(Pediatric)
Aryl fused azapolycyclic compounds 10 Nov, 2020
(3 years ago)
Expired
US6410550 Aryl fused azapolycyclic compounds 10 May, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chantix's drug page


3. Inlyta

Inlyta is protected by 9 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10869924
(Pediatric)
PD-L1 antagonist combination treatments 12 Jul, 2037
(12 years from now)
Active
US10869924 PD-L1 antagonist combination treatments 12 Jan, 2037
(12 years from now)
Active
US10570202
(Pediatric)
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer 03 Aug, 2035
(10 years from now)
Active
US10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer 03 Feb, 2035
(10 years from now)
Active
US8791140
(Pediatric)
Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals 14 Jun, 2031
(6 years from now)
Active
US8791140 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals 14 Dec, 2030
(6 years from now)
Active
US6534524
(Pediatric)
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 29 Oct, 2025
(1 year, 14 days from now)
Active
US6534524 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 29 Apr, 2025
(6 months from now)
Active
US7141581 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 30 Jun, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inlyta's drug page


4. Pristiq

Pristiq is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8269040 Derivatives of venlafaxine and methods of preparing and using the same 05 Jul, 2027
(2 years from now)
Active
US6673838 Succinate salt of O-desmethyl-venlafaxine 01 Mar, 2022
(2 years ago)
Expired
US6673838 Succinate salt of O-desmethyl-venlafaxine 11 Feb, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pristiq's drug page


5. Rapamune

Rapamune is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5989591
(Pediatric)
Rapamycin formulations for oral administration 11 Sep, 2018
(6 years ago)
Expired
US5989591 Rapamycin formulations for oral administration 11 Mar, 2018
(6 years ago)
Expired
US5536729
(Pediatric)
Rapamycin formulations for oral administration 30 Mar, 2014
(10 years ago)
Expired
US5100899
(Pediatric)
Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof 07 Jan, 2014
(10 years ago)
Expired
US5536729 Rapamycin formulations for oral administration 30 Sep, 2013
(11 years ago)
Expired
US5100899 Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof 07 Jul, 2013
(11 years ago)
Expired
US5403833
(Pediatric)
Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof 04 Oct, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapamune's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Torisel

Torisel is protected by 14 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8791097
(Pediatric)
Anti-tumor activity of CCI-779 in papillary renal cell cancer 10 Nov, 2032
(8 years from now)
Active
US8791097 Anti-tumor activity of CCI-779 in papillary renal cell cancer 10 May, 2032
(7 years from now)
Active
US8026276
(Pediatric)
Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant 20 Jul, 2026
(1 year, 9 months from now)
Active
US8026276 Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant 20 Jan, 2026
(1 year, 3 months from now)
Active
US8299116
(Pediatric)
CCI-779 concentrate formulations 25 Jan, 2024
(8 months ago)
Expired
US8455539
(Pediatric)
CCI-779 concentrate formulations 25 Jan, 2024
(8 months ago)
Expired
US8722700
(Pediatric)
CCI-779 formulations for parenteral administration 25 Jan, 2024
(8 months ago)
Expired
US8299116 CCI-779 concentrate formulations 25 Jul, 2023
(1 year, 2 months ago)
Expired
US8455539 CCI-779 concentrate formulations 25 Jul, 2023
(1 year, 2 months ago)
Expired
US8722700 CCI-779 formulations for parenteral administration 25 Jul, 2023
(1 year, 2 months ago)
Expired
USRE44768
(Pediatric)
Rapamycin hydroxyesters 15 Aug, 2019
(5 years ago)
Expired
USRE44768 Rapamycin hydroxyesters 15 Feb, 2019
(5 years ago)
Expired
US5362718
(Pediatric)
Rapamycin hydroxyesters 18 Oct, 2014
(9 years ago)
Expired
US5362718 Rapamycin hydroxyesters 18 Apr, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Torisel's drug page


7. Tygacil

Tygacil is protected by 8 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8372995 Crystalline solid forms of tigecycline and methods of preparing same 08 Oct, 2030
(5 years from now)
Active
US7879828 Tigecycline compositions and methods of preparation 05 Feb, 2029
(4 years from now)
Active
US8975242 Tigecycline compositions and methods of preparation 24 Oct, 2028
(4 years from now)
Active
US10588975 Tigecycline compositions and methods of preparation 13 Mar, 2026
(1 year, 4 months from now)
Active
US9254328 Tigecycline compositions and methods of preparation 13 Mar, 2026
(1 year, 4 months from now)
Active
US9694078 Tigecycline compositions and methods of preparation 13 Mar, 2026
(1 year, 4 months from now)
Active
USRE40183 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines 09 Apr, 2016
(8 years ago)
Expired
USRE40086 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines 25 Jun, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tygacil's drug page


8. Vfend

Vfend is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6632803 Pharmaceutical formulations containing voriconazole 02 Jun, 2018
(6 years ago)
Expired
US5567817 Triazole antifungal agents 24 May, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vfend's drug page


9. Xalkori

Xalkori is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8217057 Polymorphs of a c-MET/HGFR inhibitor 06 Nov, 2029
(5 years from now)
Active
US7858643 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors 08 Oct, 2029
(4 years from now)
Active
US7825137 Method of treating abnormal cell growth 12 May, 2027
(2 years from now)
Active
US7230098 Aminoheteroaryl compounds as protein kinase inhibitors 26 Aug, 2025
(10 months from now)
Active
US8785632 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors 01 Mar, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xalkori's drug page


10. Xeljanz

Xeljanz is protected by 8 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE41783 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2025
(1 year, 1 month from now)
Active
US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate 25 Mar, 2023
(1 year, 6 months ago)
Expired
US7301023 Chiral salt resolution 23 May, 2022
(2 years ago)
Expired
US6956041 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7091208 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7265221 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7301023 Chiral salt resolution 08 Dec, 2020
(3 years ago)
Expired
US7842699 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz's drug page


11. Zmax

Zmax is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6984403 Azithromycin dosage forms with reduced side effects 14 Feb, 2024
(7 months ago)
Expired
US7887844 Multiparticulate crystalline drug compositions having controlled release profiles 14 Feb, 2024
(7 months ago)
Expired
US6268489 Azithromycin dihydrate 31 Jul, 2018
(6 years ago)
Expired
US6068859 Controlled-release dosage forms of Azithromycin 30 May, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zmax's drug page